James O’Donnell

James O’Donnell

Professor of Vascular Biology and Director of the Irish Centre for Vascular Biology

Professor O’Donnell received his medical degree from Trinity College Dublin in 1990. After internship and medical residency in Australia, he completed clinical haematology training in the Hammersmith and Royal Free Hospitals in London. In 1998, he obtained a Medical Research Council Training Fellowship, and was awarded his PhD by Imperial College London in 2001. He subsequently completed a Post-Doctoral Fellowship in the Hammersmith Hospital, and was appointed as Senior Lecturer in Imperial College in 2004. He is a Fellow of both the Royal College of Physicians of Ireland, and the Royal College of Pathologists (UK). Following his return to Ireland in 2005, he became the first clinician scientist to receive the prestigious Science Foundation Ireland President of Ireland Young Investigator award. He is currently Professor of Vascular Biology in the Royal College of Surgeons in Ireland and Director of the recently established Irish Centre for Vascular Biology. The Haemostasis Research laboratory led by Prof. O’Donnell has been awarded more than £12 million in peer-reviewed grant funding since 2006. In addition to the National Children’s Research Centre (NCRC), his research programme has been funded by Science Foundation Ireland, the Health Research Board (HRB), the Irish Heart Foundation, the Wellcome Trust and the. Prof O’Donnell’s laboratory has focussed on basic research related to different aspects of vascular biology in relation to clinical bleeding and thrombosis. He has published more than 100 publications in high impact peer reviewed journals (including the New England Journal of Medicine, Blood, ATVB and J Biol Chem). On the basis of this research, he has also been invited to give numerous lectures at the most prestigious national and international haematology meetings, including the American Society of Hematology Annual Meeting, the Gordon Conference in Hemostasis and the Congress of the International Society for Thrombosis and Haemostasis.

James O’Donnell

Professor of Vascular Biology and Director of the Irish Centre for Vascular Biology

Judicael Fazavana
Position: Postdoctoral Researcher

Dr Fazavana is the senior postdoctoral researcher working on Prof. O’Donnell’s NCRC supported project on Malaria.

Azaz Ahmad
Position: Postdoctoral Researcher

Dr Ahmad is the senior postdoctoral researcher working on Prof. O’Donnell’s NCRC supported project on Sickle Cell Disease.

Defining the molecular mechanisms through which von Willebrand factor modulates the pathogenesis of childhood cerebral malaria - the NCRC Malaria Research Consortium

The global morbidity and mortality caused by malaria infection are staggering. Between 300 million and 500 million cases of clinical malaria occur each year, resulting in more than 500,000 deaths. Unfortunately, the majority of these deaths (~80%) occur in African children under age five. Consequently, malaria constitutes one of the leading causes of death in young children worldwide. Indeed the United Nations estimates that malaria is responsible for the death of a child in sub-Saharan Africa every 30 seconds. Cerebral malaria (CM) is a life-threatening complication of malaria infection. Young children with CM typically present to hospital with severe headache and drowsiness. Unfortunately, as the malaria infection worsens, the children rapidly progress to develop confusion, decreased consciousness and unrousable coma. Although effective anti-malarial drugs have been developed, in up to 20% of children CM still proves fatal. Furthermore, 20% of the children who survive CM are left with long term complications including learning difficulties and memory impairment. In spite of the significant mortality and morbidity associated with CM, the effects if the malaria parasite in causing disease remain poorly understood. This lack of understanding has impeded the development of new and much needed treatment options for children who develop CM. To further investigate the biology underlying CM in children, we have established a Malaria Research Consortium. This Consortium includes collaborators in Dublin, the Liverpool School of Tropical Medicine, University of Sydney and Blantyre in Malawi. In previous studies, this Consortium has identified a novel role for a specific blood clotting protein called von Willebrand factor (VWF) in malaria. In the blood, this clotting protein is able to bind to red cells infected with malaria parasites. In this study, the Consortium will investigate further how VWF influences malaria progression. Ultimately, we hope that insights into how VWF is important in children with malaria infection may provide new treatment options for children with CM.

The Sickle Vascular Ireland Consortium (SiVIC) project

Although sickle cell disease (SCD) is associated with significant paediatric morbidity and mortality, the pathophysiology underlying micro-vascular occlusion in SCD remains poorly understood. However, a critical step in this vascular occlusion involves adhesion of sickle erythrocytes to vascular endothelial cells (EC). Interestingly, emerging data suggests a novel role for the plasma glycoprotein von Willebrand factor (VWF) in modulating the EC adhesion of sickle erythrocytes. The objective of the current study is to define the molecular mechanisms through which VWF, and in particular ultra-large multimeric forms of VWF, influence SCD pathogenesis in children. Through this application, we propose to develop a new Sickle Vascular Ireland Consortium (SiVIC). SiVIC will unite the clinical resource and deep phenotypic data already collected in the Irish Sickle Centre in OLCHC with the vascular research expertise in the Irish Centre for Vascular Biology (ICVB) network in order to investigate the biology involved in SCD vascular occlusion. In this first SiVIC study, we will specifically investigate the hypothesis that dysfunction of the VWF-ADAMTS13 axis in children with SCD leads to the pathological UL-VWF multimer accumulation and thereby promotes microvascular occlusion. Sickle cell disease (SCD) is responsible for major paediatric morbidity and mortality. Globally, more than 1000 children with SCD are born every day. Unfortunately, in resource-poor countries, half of these children die before reaching five years of age and less than 10% actually survive to adulthood. Even in developed countries, SCD continues to be associated with significant paediatric morbidity. For example, 10% of US children with SCD develop symptomatic strokes that commonly result in learning problems and lifelong disabilities. Consequently, there is an urgent unmet need to develop novel adjunctive therapies to improve clinical outcomes in children with SCD.

The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Meaney JFM, O'Donnell JS, Bridgewood C, Harbison J, McGonagle D, 2022 May 11, Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules. Stroke, DOI: 10.1161/STROKEAHA.121.038056
Doherty D, Lavin M, Byrne MB, Nolan M, O'Sullivan JM, Ryan K, O'Connell NM, Haberichter SL, Christopherson P, Di Paola J, James PD, O'Donnell JS, 2022 May 6, Enhanced VWF clearance in Low VWF pathogenesis - limitations of VWFpp/VWF:Ag ratio and clinical significance. Blood Adv, DOI: 10.1182/bloodadvances.2022007340
Sadler B, Castaman G, O'Donnell JS, 2022 May, von Willebrand disease and von Willebrand factor. Haemophilia, DOI: 10.1111/hae.14547
O'Regan N, Gegenbauer K, Gleeson EM, Fukudome K, O'Sullivan JM, Drakeford C, Dalton N, Chion A, Brophy TM, Smith OP, Preston RJS, O'Donnell JS, 2022 Apr 21, Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. Haematologica, DOI: 10.3324/haematol.2021.280450
Trinh DN, Gardner RA, Franciosi AN, McCarthy C, Keane MP, Soliman MG, O'Donnell JS, Meleady P, Spencer DIR, Monopoli MP, 2022 Mar 28, Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery. ACS Nano, DOI: 10.1021/acsnano.1c09564
O'Donnell AS, Fazavana J, O'Donnell JS, 2022 Jan, The von Willebrand factor - ADAMTS-13 axis in malaria. Res Pract Thromb Haemost, DOI: 10.1002/rth2.12641
Musgrave KM, Power K, Laffan M, O'Donnell JS, Thachil J, Maraveyas A, 2022 Mar, Practical treatment guidance for cancer-associated thrombosis - Managing the challenging patient: A consensus statement. Crit Rev Oncol Hematol, DOI: 10.1016/j.critrevonc.2022.103599
McGonagle D, Kearney MF, O'Regan A, O'Donnell JS, Quartuccio L, Watad A, Bridgewood C, 2022 Feb, Therapeutic implications of ongoing alveolar viral replication in COVID-19. Lancet Rheumatol, DOI: 10.1016/S2665-9913(21)00322-2
Fogarty H, Karampini E, O'Donnell AS, Ward SE, O'Sullivan JM, O'Donnell JS, Irish COVID-19 Vasculopathy Study (iCVS) investigators., 2022 Jan, Persistent endotheliopathy in the pathogenesis of long COVID syndrome - Reply to comment from von Meijenfeldt et al. J Thromb Haemost, DOI: 10.1111/jth.15578
O'Donovan M, Quinn E, Johnston K, Singleton E, Benson J, O'Mahony B, Noone D, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM, Mahlangu J, 2021 Oct, Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. Res Pract Thromb Haemost, DOI: 10.1002/rth2.12602
Lavin M, Sánchez Luceros A, Kouides P, Abdul-Kadir R, O'Donnell JS, Baker RI, Othman M, Haberichter SL, ISTH Von Willebrand Factor and Women’s Health Scientific Subcommittees., 2022 Jan, Examining international practices in the management of pregnant women with von Willebrand disease. J Thromb Haemost, DOI: 10.1111/jth.15561
O'Donovan M, Singleton E, Roche S, McGowan M, Benson J, Bergin C, Bird R, Byrne M, Duggan C, Gilmore R, Ryan K, Dougall A, O'Donnell JS, O'Connell NM, 2021 Nov, Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. Haemophilia, DOI: 10.1111/hae.14426
Kalot MA, Husainat N, El Alayli A, Abughanimeh O, Diab O, Tayiem S, Madoukh B, Dimassi AB, Qureini A, Ameer B, Eikenboom JCJ, Giraud N, McLintock C, McRae S, Montgomery RR, O'Donnell JS, Scappe N, Sidonio RF, Brignardello-Petersen R, Flood VH, Connell NT, James PD, Mustafa RA, 2022 Jan 11, von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Adv, DOI: 10.1182/bloodadvances.2021005430
Kalot MA, Husainat N, Tayiem S, El Alayli A, Dimassi AB, Diab O, Abughanimeh O, Madoukh B, Qureini A, Ameer B, Di Paola J, Eikenboom JCJ, Jacobs-Pratt V, McLintock C, Montgomery R, O'Donnell JS, Sidonio R, Brignardello-Petersen R, Flood V, Connell NT, James PD, Mustafa RA, 2021 Dec 14, Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Adv, DOI: 10.1182/bloodadvances.2021004368
Baker RI, O'Donnell JS, 2021 Nov 11, How I treat bleeding disorder of unknown cause. Blood, DOI: 10.1182/blood.2020010038
Thomas W, Downes K, Evans G, Gidley G, Lowe G, MacDonald S, Obaji S, O'Donnell JS, Palmer B, Pinto F, Desborough M, 2021 Nov, Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. J Thromb Haemost, DOI: 10.1111/jth.15492
Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, Englert H, Byrne M, Bergin C, O'Sullivan JM, Martin-Loeches I, Nadarajan P, Bannan C, Mallon PW, Curley GF, Preston RJS, Rehill AM, McGonagle D, Ni Cheallaigh C, Baker RI, Renné T, Ward SE, O'Donnell JS, Irish COVID-19 Vasculopathy Study (iCVS) investigators., 2021 Oct, Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost, DOI: 10.1111/jth.15490
Krishnaswamy S, Ageno W, Arabi Y, Barbui T, Cannegieter S, Carrier M, Cleuren AC, Collins P, Panicot-Dubois L, Freedman JE, Freson K, Hogg P, James AH, Kretz CA, Lavin M, Leebeek FWG, Li W, Maas C, Machlus K, Makris M, Martinelli I, Medved L, Neerman-Arbez M, O'Donnell JS, O'Sullivan J, Rajpurkar M, Schroeder V, Spiegel PC Jr, Stanworth SJ, Green L, Undas A, 2021 Jul, Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost, DOI: 10.1002/rth2.12532
Bakeer N, Dover S, Babyn P, Feldman BM, von Drygalski A, Doria AS, Ignas DM, Abad A, Bailey C, Beggs I, Chang EY, Dunn A, Funk S, Gibikote S, Goddard N, Hilliard P, Keshava SN, Kruse-Jarres R, Li Y, Lobet S, Manco-Johnson M, Martinoli C, O'Donnell JS, Papakonstantinou O, Pergantou H, Poonnoose P, Querol F, Srivastava A, Steiner B, Strike K, Timmer M, Tyrrell PN, Vidarsson L, Blanchette VS, 2021 Jul, Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Res Pract Thromb Haemost, DOI: 10.1002/rth2.12531
Lavin M, Elder PT, O'Keeffe D, Enright H, Ryan E, Kelly A, El Hassadi E, McNicholl FP, Benson G, Le GN, Byrne M, Ryan K, O'Connell NM, O'Donnell JS, 2021 Oct, Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations. Br J Haematol, DOI: 10.1111/bjh.17613
Ward S, O'Sullivan JM, O'Donnell JS, 2021 Oct, The Biological Significance of von Willebrand Factor O-Linked Glycosylation. Semin Thromb Hemost, DOI: 10.1055/s-0041-1726373
Ward SE, Fogarty H, Karampini E, Lavin M, Schneppenheim S, Dittmer R, Morrin H, Glavey S, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Mallon PW, Curley GF, Baker RI, Budde U, O'Sullivan JM, O'Donnell JS, Irish COVID-19 Vasculopathy Study (iCVS) investigators., 2021 Aug, ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost, DOI: 10.1111/jth.15409
O'Donnell JS, Peyvandi F, Martin-Loeches I, 2021 Aug, Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med, DOI: 10.1007/s00134-021-06419-w
O'Donovan M, Bergin C, Quinn E, Singleton E, Roche S, Benson J, Bird R, Byrne M, Duggan C, Gilmore R, Ryan K, O'Donnell JS, O'Connell NM, 2021 Jul, Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort. Haemophilia, DOI: 10.1111/hae.14307
Ward SE, O'Sullivan JM, Moran AB, Spencer DIR, Gardner RA, Sharma J, Fazavana J, Monopoli M, McKinnon TAJ, Chion A, Haberichter S, O'Donnell JS, 2022 Mar 1, Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. Haematologica, DOI: 10.3324/haematol.2020.274720
O'Donnell JS, 2021 Mar, Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease. Semin Thromb Hemost, DOI: 10.1055/s-0041-1722864
Rehill AM, McCluskey S, O'Donnell JS, Dockal M, Preston RJS, iPATH Study Group., 2021 Mar, Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia. Semin Thromb Hemost, DOI: 10.1055/s-0041-1723769
Townsend L, Fogarty H, Dyer A, Martin-Loeches I, Bannan C, Nadarajan P, Bergin C, O'Farrelly C, Conlon N, Bourke NM, Ward SE, Byrne M, Ryan K, O'Connell N, O'Sullivan JM, Ni Cheallaigh C, O'Donnell JS, 2021 Apr, Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost, DOI: 10.1111/jth.15267
James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, R Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA, 2021 Jan 12, ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv, DOI: 10.1182/bloodadvances.2020003265
Connell NT, James PD, Brignardello-Petersen R, Abdul-Kadir R, Ameer B, Arapshian A, Couper S, Di Paola J, Eikenboom J, Giraud N, Grow JM, Haberichter S, Jacobs-Pratt V, Konkle BA, Kouides P, Laffan M, Lavin M, Leebeek FWG, McLintock C, McRae S, Montgomery R, O'Brien SH, O'Donnell JS, Ozelo MC, Scappe N, Sidonio R, Tosetto A, Weyand AC, Kalot MA, Husainat N, Mustafa RA, Flood VH, 2021 Jan 26, von Willebrand disease: proposing definitions for future research. Blood Adv, DOI: 10.1182/bloodadvances.2020003620
Karampini E, O'Donnell JS, 2021 Jan, Correcting dominant-negative von Willebrand disease. J Thromb Haemost, DOI: 10.1111/jth.15123
Doherty D, Lavin M, O'Sullivan JM, Ryan K, O'Connell NM, Dougall A, Byrne M, Rafferty M, Doyle MM, Di Paola J, James PD, O'Donnell JS, 2021 Mar, Management of elective procedures in low von Willebrand factor patients in the LoVIC study. J Thromb Haemost, DOI: 10.1111/jth.15220
Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL, Clarke J, Boylan M, Alalqam R, Worrall AP, Kelly C, de Barra E, Glavey S, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Townsend L, Mallon PW, O'Sullivan JM, O'Donnell JS, Irish COVID-19 Vasculopathy Study (ICVS) Investigators., 2021 Feb, Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol, DOI: 10.1111/bjh.17273
O'Donghaile D, Jenkins PV, McGrath RT, Preston L, Field SP, Ward SE, O'Sullivan JM, O'Donnell JS, 2020 Oct 27, Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. Sci Rep, DOI: 10.1038/s41598-020-75462-2
O'Donovan M, Buckley C, Benson J, Roche S, McGowan M, Parkinson L, Byrne P, Rooney G, Bergin C, Walsh D, Bird R, McGroarty F, Fogarty H, Smyth E, Ahmed S, O'Donnell JS, Ryan K, O'Mahony B, Dougall A, O'Connell NM, 2020 Nov, Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemic. Haemophilia, DOI: 10.1111/hae.14156
Murphy SJX, Lim ST, Hickey F, Kinsella JA, Smith DR, Tierney S, Egan B, Feeley TM, Murphy SM, Collins DR, Coughlan T, O'Neill D, Harbison JA, Madhavan P, O'Neill SM, Colgan MP, O'Donnell JS, O'Sullivan JM, Hamilton G, McCabe DJH, 2021 Jan, von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli. Thromb Haemost, DOI: 10.1055/s-0040-1715440
McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C, 2020 Aug, Pulmonary intravascular coagulopathy in COVID-19 pneumonia - Authors' reply. Lancet Rheumatol, DOI: 10.1016/S2665-9913(20)30174-0
McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C, 2020 Jul, Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol, DOI: 10.1016/S2665-9913(20)30121-1
Ward SE, O'Sullivan JM, O'Donnell JS, 2020 Dec 17, The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood, DOI: 10.1182/blood.2020005843
O'Donnell JS, 2020 Jul 14, Low VWF: insights into pathogenesis, diagnosis, and clinical management. Blood Adv, DOI: 10.1182/bloodadvances.2020002038
O'Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O'Donnell JS, 2020 Aug, Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol, DOI: 10.1016/S2352-3026(20)30215-5
Turecek PL, Johnsen JM, Pipe SW, O'Donnell JS, iPATH study group., 2020 Jul, Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia, DOI: 10.1111/hae.14078
Moxon CA, Alhamdi Y, Storm J, Toh JMH, McGuinness D, Ko JY, Murphy G, Lane S, Taylor TE, Seydel KB, Kampondeni S, Potchen M, O'Donnell JS, O'Regan N, Wang G, García-Cardeña G, Molyneux M, Craig AG, Abrams ST, Toh CH, 2020 Jul 14, Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria. Blood Adv, DOI: 10.1182/bloodadvances.2019001258
Gleeson EM, Rehill AM, Willis Fox O, Ni Ainle F, McDonnell CJ, Rushe HJ, McCluskey S, O'Donnell JS, Preston RJS, 2020 Jun 9, Apolipoprotein A-I enhances activated protein C cytoprotective activity. Blood Adv, DOI: 10.1182/bloodadvances.2019001316
McGonagle D, Plein S, O'Donnell JS, Sharif K, Bridgewood C, 2020 Jul, Increased cardiovascular mortality in African Americans with COVID-19. Lancet Respir Med, DOI: 10.1016/S2213-2600(20)30244-7
O'Sullivan JM, Ward S, Fogarty H, O'Donnell JS, 2020 Jul, More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia'. Br J Haematol, DOI: 10.1111/bjh.16845
Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, Bacon CL, Gaule R, Gillett A, Byrne M, Ryan K, O'Connell N, O'Sullivan JM, Conlon N, O'Donnell JS, 2020 Jun, More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol, DOI: 10.1111/bjh.16791
Fogarty H, Doherty D, O'Donnell JS, 2020 Nov, New developments in von Willebrand disease. Br J Haematol, DOI: 10.1111/bjh.16681
Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, Bacon CL, Gaule R, Gillett A, Byrne M, Ryan K, O'Connell N, O'Sullivan JM, Conlon N, O'Donnell JS, 2020 Jun, COVID19 coagulopathy in Caucasian patients. Br J Haematol, DOI: 10.1111/bjh.16749
O'Sullivan JM, O'Donnell JS, 2020 Apr 7, Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Mol Med, DOI: 10.15252/emmm.202012143
Fazavana J, Brophy TM, Chion A, Cooke N, Terraube V, Cohen J, Parng C, Pittman D, Cunningham O, Lambert M, O'Donnell JS, O'Sullivan JM, 2020 Jun, Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation. J Thromb Haemost, DOI: 10.1111/jth.14785
O'Donnell JS, Lavin M, 2019 Dec 6, Perioperative management of patients with von Willebrand disease. Hematology Am Soc Hematol Educ Program, DOI: 10.1182/hematology.2019000065
Ward S, O'Sullivan JM, O'Donnell JS, 2019 Jul, von Willebrand factor sialylation-A critical regulator of biological function. J Thromb Haemost, DOI: 10.1111/jth.14471
O'Donnell JS, O'Sullivan JM, Preston RJS, 2019 Jul, Advances in understanding the molecular mechanisms that maintain normal haemostasis. Br J Haematol, DOI: 10.1111/bjh.15872
Preston RJS, O'Sullivan JM, O'Donnell JS, 2019 Jul, Advances in understanding the molecular mechanisms of venous thrombosis. Br J Haematol, DOI: 10.1111/bjh.15869
Aguila S, Lavin M, Dalton N, Patmore S, Chion A, Trahan GD, Jones KL, Keenan C, Brophy TM, O'Connell NM, Ryan K, Byrne M, Nolan M, Patel A, Preston RJS, James P, Di Paola J, O'Sullivan JM, O'Donnell JS, 2019 Apr 4, Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, DOI: 10.1182/blood-2018-09-874636
Aguila S, O'Donnell JS, 2019 Mar, Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone. J Thromb Haemost, DOI: 10.1111/jth.14353
Dunne E, Qi QM, Shaqfeh ES, O'Sullivan JM, Schoen I, Ricco AJ, O'Donnell JS, Kenny D, 2019 Mar 21, Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, DOI: 10.1182/blood-2018-06-855528
Lavin M, O'Donnell JS, 2019 Feb 21, How I treat low von Willebrand factor levels. Blood, DOI: 10.1182/blood-2018-10-844936

Please visit PubMed for more information on James O’Donnell's publications

Name:Prof Owen Smith
Institution:Children's Health Ireland, Crumlin
Name:Prof Alister Craig
DepartmentBiological Sciences
Institution:Liverpool School of Tropical Medicine
Name:Prof Matthew Campbell
Institution:Trinity College Dublin
Name:Prof Corrina McMahon
Institution:Children's Health Ireland, Crumlin
Name:Dr Michelle Lavin
DepartmentIrish Centre for Vascular Biology
Institution:Royal College of Surgeons in Ireland